The diabetes drug Invokana® has been linked to cases of kidney failure, heart attack, ketoacidosis, bone fractures and other serious injuries.
In May 2015, the Food and Drug Administration issued a warning that SGLT2 inhibitors such as Invokana may lead to high levels of acid accumulating in the blood; known as diabetic ketoacidosis. Recent studies reveal that Invokana and other SGLT2 inhibitors have other serious side effects, including increased risks of kidney failure and heart attacks.
To find out if you, a friend or a family member may be eligible to pursue an Invokana injury claim, call 1-800-ELK-OHIO or contact us online for a free, no obligation case review.
According to a recent report published in the Journal of the American Medical Association, nearly half of all American adults have type 2 diabetes or prediabetes. Many individuals chose to take Invokana over other drugs because of advertising claims that the drug may result in weight loss.
Invokana Side Effects
Financial compensation may be available through an Invokana lawsuit for individuals who have suffered these side effects:
- Kidney failure
- Diabetic ketoacidosis
- Heart attack
- Bone fractures
- Wrongful death
What is Invokana?
Invokana (canagliflozin) is a medication used to treat type 2 diabetes. Introduced in 2013, Invokana was the first of a new class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs work by blocking the SGLT2 protein in the kidney, allowing excess glucose to be eliminated through the urine.
Manufactured by Johnson & Johnson, Invokana has become a blockbuster type 2 diabetes treatment, with sales of $278 million in the first quarter of 2015 alone. Unfortunately, mounting evidence indicates that the drug maker may have withheld critical information about potential risks.
If you suffered serious harm after taking Invokana or another SGLT2 inhibitor to treat type 2 diabetes, contact the experienced Invokana lawyers at Elk & Elk. As a result of the drug maker’s failure to adequately warn, financial compensation may be available for medical bills, lost wages and pain and suffering.
Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. (2015, May 5). Accessed 3 Sept. 2015.
Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA. 2015;314(10):1021-1029. doi:10.1001/jama.2015.10029.
Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015 Aug ;100(8):2849-52. doi: 10.1210/jc.2015-1884. Epub 2015 Jun 18.
This website is not intended to provide medical advice. The FDA states that patients should not stop or change their diabetes medicines without talking to their physician. If you believe you have signs or symptoms of ketoacidosis, your physician can evaluate you for the presence of acidosis, including ketoacidosis, and advise you on the proper treatment if acidosis is confirmed.
Invokana and Invokamet are registered trademarks of Janssen Pharmaceuticals, Inc. Farxiga and Xigduois XR are registered trademarks of AstraZeneca Pharmaceuticals LP. Jardiance and Glyxambi are registered trademarks of Boehringer Ingelheim Pharmaceuticals, Inc. The use of these trademarks is solely for product identification and informational purposes.